Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Zeaxanthin is a naturally occurring carotenoid and one of the most common carotenoid alcohols found in nature. It is crucial to the xanthophyll cycle. It is the pigment that gives paprika (made from bell peppers), corn, saffron, wolfberries, and many other plants and microbes their distinctive color.
Targets |
Microbial Metabolite; Human Endogenous Metabolite
|
---|---|
ln Vitro |
Plant leaves contain lutein and zeaxanthin that are primarily attached to proteins. The xanthophylls are condensed and purified into chromoplasts, which are found dissolved in membranes, in fruits and flower petals. In humans and other higher animals, lipophilic tissues like adipose tissue are where lutein and zeaxanthin accumulate. Lipoproteins formulate these pigments in the blood, most likely in a way that is deeply non-phospholipid-based. While hydrocarbon carotenoids are preferentially concentrated in the LDL fraction, up to 75% of them, lutein and zeaxanthin are equally distributed in the blood's LDL and HDL fractions [3].
|
References |
[1]. Bone RA, et al. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp Eye Res. 1997 Feb;64(2):211-8.
[2]. Elbaz-Hayoun S, et al. Evaluation of antioxidant treatments for the modulation of macrophage function in the context of retinal degeneration. Mol Vis. 2019 Sep 5;25:479-488. [3]. Krinsky NI, et al. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye.Annu Rev Nutr. 2003;23:171-201. |
Molecular Formula |
C40H56O2
|
---|---|
Molecular Weight |
568.8715
|
Exact Mass |
568.43
|
Elemental Analysis |
C, 84.45; H, 9.92; O, 5.62
|
CAS # |
144-68-3
|
Related CAS # |
144-68-3
|
Appearance |
Solid powder
|
SMILES |
CC1=C(C(C[C@@H](C1)O)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(C[C@H](CC2(C)C)O)C)\C)\C)/C)/C
|
InChi Key |
JKQXZKUSFCKOGQ-QAYBQHTQSA-N
|
InChi Code |
InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-24,35-36,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36-/m1/s1
|
Chemical Name |
(1R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethylcyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-3-en-1-ol
|
Synonyms |
beta-Carotene-3,3'-diol; Xanthophyll 3; Zeaxanthin; Zeaxanthol; Anchovyxanthin
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
THF: ≥ 10 mg/mL (~17.6 mM)
DMSO: < 1 mg/mL |
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7579 mL | 8.7894 mL | 17.5787 mL | |
5 mM | 0.3516 mL | 1.7579 mL | 3.5157 mL | |
10 mM | 0.1758 mL | 0.8789 mL | 1.7579 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05232409 | Recruiting | Biological: Zeaxanthin Combination Product: Zeaxanthin Plus Pembrolizumab |
Cancer Metastatic Metastatic Solid Tumor |
Valley Health System | April 17, 2022 | Phase 1 |
NCT00564902 | Completed | Drug: 3R 3'R Zeaxanthin Dietary Supplement: Lutein |
Cognition Disorders Age Related Macular Degeneration |
Chrysantis, Inc. | November 2007 | Not Applicable |
NCT03750968 | Completed | Drug: Carotenoid Group Dietary Supplement: Control Group |
Nutrient Deficiency Pregnancy Related |
Paul S. Bernstein | September 26, 2019 | Phase 2 |
NCT00564902 | Completed | Drug: 3R 3'R Zeaxanthin Dietary Supplement: Lutein |
Age Related Macular Degeneration Cognition Disorders |
Paul S. Bernstein | November 2007 | Not Applicable |
NCT00345176 | Completed | Dietary Supplement: Lutein/ zeaxanthin Dietary Supplement: DHA/EPA |
Cataract Age-related Macular Degeneration |
National Eye Institute (NEI) |
September 2006 | Phase 3 |